AI-powered neurotechnology is making significant strides at the SOZO Brain Center in Cyprus, as evidenced by Chief Scientist Demetris Skourides’ recent visit. The visit, which took place on Monday, was designed to showcase the centre’s pioneering research activities and its commitment to advancing neuromodulation and AI-enabled medicine.
Ai-powered neurotechnology: Engaging with Cyprus’ Innovation Landscape
During his visit, Skourides met with key figures at SOZO, including chief executive officer Matthew Papadopoulos and brain.space CEO Yair Levy, along with SOZO’s multidisciplinary research team. The initiative is part of a larger effort to engage with Cyprus’ research and innovation ecosystem, promoting applied research, commercialisation, and global partnerships.
Showcasing Cutting-Edge Projects
The programme featured presentations on ongoing projects and international collaborations, culminating in a live demonstration of the Brain Sensei AI-powered neurotechnology helmet. This innovative device is designed to collect and analyse neurophysiological data in real-time, transforming it into actionable insights for clinicians while adhering to GDPR and privacy regulations.
Building a Network of Clinical Excellence
SOZO’s research department consists of over ten neuroscientists and clinicians dedicated to enhancing the international scientific dialogue surrounding neuromodulation. Their findings have been presented at prestigious global conferences, such as the World Congress of Neurology and the International Neuromodulation Society World Congress. Additionally, plans for further publications in peer-reviewed journals are underway.
Moreover, SOZO has trained more than 150 doctors from 14 different countries in its neuromodulation protocols, with over 60 clinicians now certified as SOZO Fellows. This network has collectively treated more than 3,500 patients worldwide, demonstrating the substantial impact of SOZO’s work.
Strategic Pillars for Global Collaboration
Looking to the future, SOZO Brain Center is advancing three strategic pillars aimed at strengthening global collaboration in neuromodulation. Firstly, it plans to develop a Clinical Trials Centre that adheres to UK and US standards, aimed at generating clinical evidence for neuromodulation therapies.
Secondly, the centre is establishing a continuing medical education (CME)-accredited e-learning platform that will facilitate ongoing training and certification for clinicians globally. Lastly, SOZO is creating train-the-trainer workshops to broaden the faculty of trainers, thereby scaling access to its innovative methodologies.
Expanding International Partnerships
Through its SOZO Partnerships initiative, the organisation has already established co-branded clinics in several major cities, including Berlin, Vienna, Melbourne, and Athens, integrating its treatment protocols into local medical practices. This expansion reflects SOZO’s commitment to bringing its cutting-edge therapies to a wider audience.
AI’s Role in Healthcare Innovation
In tandem with its clinical efforts, SOZO is also focused on developing agentic AI agents specifically for healthcare applications. Following his visit, Skourides remarked on the growing strength of Cyprus’ research and innovation ecosystem, highlighting the significant role played by local scientists, clinicians, and entrepreneurs in advancing solutions with a global impact.
“My visit to SOZO Brain Center offered valuable insights into the pioneering research being conducted in Cyprus, the international collaborations being forged, and the ways in which innovation here contributes to the broader scientific and medical community,” he stated.
Commitment to Advancing Medical Technologies
According to Skourides, it is exciting to witness how artificial intelligence is being integrated into healthcare in Cyprus. He noted that SOZO’s commitment to developing technologies like Agentic AI aligns with the broader investment by Cypriot innovation companies in strengthening their research and development capabilities, which is part of Cyprus’ national Research and Development Strategy for 2024–2026.
Matthew Papadopoulos echoed this sentiment, expressing his pride in welcoming the Chief Scientist to showcase the progress made by SOZO. “At SOZO, we are advancing a first-of-its-kind agentic AI platform with brain.space, creating global standards in neuromodulation and building an international network of trained physicians who are already transforming patient care,” he stated.
Intellectual Property and Future Innovations
SOZO Brain Center holds a robust intellectual property portfolio that underpins its growth and international credibility. This includes proprietary rights to the Functional Network-Oriented Neuromodulation Protocol, a clinically validated methodology that integrates various neuromodulation modalities for chronic neurological and mental health conditions. The organisation also manages copyrighted physician manuals, treatment SOPs, and patient education materials, all of which are designed to ensure ethical application and scalability of its methods.
Furthermore, SOZO is poised to develop patentable innovations in neuromodulation device manufacturing by late 2026, reinforcing Cyprus’ position as a global reference hub for neuromodulation treatments. This strategic approach not only safeguards SOZO’s methodologies but also enhances its ability to expand its impact in the international medical community.
